Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.

Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: Certain embodiments of the invention include recombinant reverse genetic systems for SARS-COV-2 virus.

Abstract: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.

Abstract: Certain embodiments of the invention include recombinant reverse genetic systems for Omicron variant of SARS-CoV-2 virus.

Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.

Abstract: Certain embodiments are directed to a stable recombinant flavivirus nucleic acid having a heterologous reporter cassette, the reporter cassette having a 5? end, a nucleotide segment encoding a reporter, and a 3? end; the 5? end of the reporter cassette encoding 25 to 38 amino acids of a flavivirus capsid protein; the 3? end of the reporter cassette encoding 25 to 38 amino acids of a flavivirus capsid protein.

Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).

Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.

Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.

Abstract: Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.

Abstract: Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.

Abstract: The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.

Abstract: The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.